Article
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2024
Lu Shun, Zhang Yiping, Zhang Guojun, Zhou Jianying, Cang Shundong, Cheng Ying, Wu Gang, Cao Peiguo, Lv Dongqing, Jian Hong, Jin Xiangming, Chen Chengshui, Tian Panwen, Wang Kai, Jiang Guanming, Chen Gongyan, Chen Qun, Zhao Hui, Ding Cuimin, Guo Renhua, Sun Guoping, Wang Bin, Jiang Liyan, Liu Zhe, Fang Jian, Yang Junquan, Zhuang Wu, Liu Yunpeng, Zhang Jian, Pan Yueyin, Chen Jun, Yu Qitao, Zhao Min, Cui Jiuwei, Li Dianming, Yi Tienan, Yu Zhuang, Yang Yan, Zhang Yan, Zhi Xiuyi, Huang Yunchao, Wu Rong, Chen Liangan, Zang Aimin, Cao Lejie, Li Qingshan, Li Xiaoling, Song Yong, Wang Donglin, Zhang Shucai, Ding Lieming, Zhang Ling, Ji Dong, Shen Zhilin
Abstract excerpt
BACKGROUND: In the initial analysis of a pivotal phase 2 single-arm study (NCT03861156), befotertinib (D-0316) showed clinical benefit with a manageable safety profile in pretreated patients with EGFR T790M mutated non-small cell lung cancer (NSCLC), including those with brain metastases. METHODS: Eligible patients received oral befotertinib of 50 mg (cohort A) or 75-100 mg (cohort B) once daily until disease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.